Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

• Published in: Nature medicine Vol. 23; no. 10; pp. 1146 - 1149
• Main Authors: Mire, Chad E, Cross, Robert W, Geisbert, Joan B, Borisevich, Viktoriya, Agans, Krystle N, Deer, Daniel J, Heinrich, Megan L, Rowland, Megan M, Goba, Augustine, Momoh, Mambu, Boisen, Mathew L, Grant, Donald S, Fullah, Mohamed, Khan, Sheik Humarr, Fenton, Karla A, Robinson, James E, Branco, Luis M, Garry, Robert F, Geisbert, Thomas W
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.10.2017; Nature Publishing Group
• Subjects: 13/1; 13/51; 631/326/596/1961; 692/699/255/2514; Animals; Antibodies; Antibodies, Monoclonal - therapeutic use; Antibodies, Neutralizing - therapeutic use; Antibodies, Viral - therapeutic use; Biomedicine; brief-communication; Cancer Research; Care and treatment; Cross Reactions; Drug dosages; Drug therapy; Enzyme-Linked Immunosorbent Assay; Fatalities; Fever; Glycoproteins; Health aspects; Humans; Immune Evasion - genetics; Immunohistochemistry; Immunology; Immunotherapy; Infectious Diseases; Lassa fever; Lassa Fever - prevention & control; Lassa virus - genetics; Macaca fascicularis; Medicine; Metabolic Diseases; Molecular Medicine; Monoclonal antibodies; Neurosciences; Plasma; Primates; Random Allocation; RNA, Viral - blood; Survival Rate; Vaccines; Viral diseases; Viral Load; Viruses

Thomas Geisbert and colleagues show that a cocktail of monoclonal antibodies protects cynomolgus monkeys from lethal Lassa fever virus infection, including when administration is delayed by more than a week after viral challenge. There are no approved treatments for Lassa fever, which is endemic to...